Top

Published in:

Open Access 01-12-2023 | Fatty Liver | Research

Dietary selenium intake in relation to non-alcoholic fatty liver disease assessed by fatty liver index and hepatic steatosis index; a cross-sectional study on the baseline data of prospective PERSIAN Kavar cohort study.

Authors: Sara Shojaei Zarghani, Nima Rahimi Kashkooli, Zahra Bagheri, Mahdy Tabatabaei, Mohammad Reza Fattahi, Ali Reza Safarpour

Published in: BMC Endocrine Disorders | Issue 1/2023

Abstract

Background

There is limited and conflicting evidence on the association between selenium and non-alcoholic fatty liver disease (NAFLD). Therefore, the present population-based cross-sectional study aimed to explore the relationship between dietary selenium intake and the risk of NAFLD.

Methods

A total of 3026 subjects from the PERSIAN (Prospective Epidemiological Research Studies in IrAN) Kavar cohort study were included in the analysis. The daily selenium intake was evaluated using a semi-quantitative food frequency questionnaire, and energy-adjusted quintiles of selenium intake (µg/day) were calculated. NAFLD was defined as the fatty liver index (FLI) ≥ 60 or the hepatic steatosis index (HSI) > 36. The association between dietary selenium intake and NAFLD was evaluated using logistic regression analysis.

Results

The prevalence rates of NAFLD were 56.4% and 51.9%, based on the FLI and HSI markers, respectively. The odds ratios (ORs) for FLI-defined NAFLD were 1.31 (95% confidence interval (CI): 1.01–1.70) and 1.50 (95% CI: 1.13–1.99) for the fourth and fifth quintiles of selenium intake, respectively, after adjustment for sociodemographic variables, smoking status, alcohol drinking, physical activity, and dietary factors (P trend = 0.002). There was also a similar association between selenium intakes and HSI-defined NAFLD (OR = 1.34 (95% CI: 1.03–1.75) for the fourth quintile and OR = 1.50 (95% CI: 1.12–2.01) for the fifth quintile of selenium intake) (P trend = 0.006).

Conclusion

In this large sample study, we observed a weak positive association between dietary selenium intake and NAFLD risk.

Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016. https://doi.org/10.1016/j.cld.2015.10.001.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016. https://doi.org/10.1002/hep.28431.

Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014. https://doi.org/10.3748/wjg.v20.i18.5320.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015. https://doi.org/10.1053/j.gastro.2014.11.039.

Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, et al. Role of Nutrition in the pathogenesis and Prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019. https://doi.org/10.7150/ijbs.30121.

Shojaei-Zarghani S, Safarpour AR, Fattahi MR, Keshtkar A. Sodium in relation with nonalcoholic fatty liver disease: a systematic review and meta-analysis of observational studies. Food Sci Nutr. 2022. https://doi.org/10.1002/fsn3.2781.

Kieliszek M, Blazejak S. Current knowledge on the importance of Selenium in Food for living organisms: a review. Molecules. 2016. https://doi.org/10.3390/molecules21050609.

Kieliszek M. Selenium–fascinating microelement, properties and sources in food. Molecules. 2019. https://doi.org/10.3390/molecules24071298.

Bhattacharya PT, Misra SR, Hussain M. Nutritional aspects of essential trace elements in oral health and disease: an extensive review. Scientifica. 2016. https://doi.org/10.1155/2016/5464373.

10.

Mehdi Y, Hornick JL, Istasse L, Dufrasne I. Selenium in the environment, metabolism and involvement in body functions. Molecules. 2013. https://doi.org/10.3390/molecules18033292.

11.

Tóth RJ, Csapó J. The role of selenium in nutrition: a review. Acta Univ Sapientiae Aliment. 2018. https://doi.org/10.2478/ausal-2018-0008.

12.

Stranges S, Sieri S, Vinceti M, Grioni S, Guallar E, Laclaustra M, et al. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health. 2010. https://doi.org/10.1186/1471-2458-10-564.

13.

Siddiqi SM, Sun C, Wu X, Shah I, Mehmood A. The correlation between dietary selenium intake and type 2 diabetes: a cross-sectional population-based study on North Chinese adults. Biomed Res Int. 2020. https://doi.org/10.1155/2020/8058463.

14.

Wei J, Zeng C, Gong Q-y, Yang H-b, Li X-x, Lei G-h, et al. The association between dietary selenium intake and diabetes: a cross-sectional study among middle-aged and older adults. Nutr J. 2015. https://doi.org/10.1186/s12937-015-0007-2.

15.

Lin J, Shen T. Association of dietary and serum selenium concentrations with glucose level and risk of diabetes mellitus: a cross sectional study of national health and nutrition examination survey, 1999–2006. J Trace Elem Med Biol. 2021. https://doi.org/10.1016/j.jtemb.2020.126660.

16.

Cardoso BR, Braat S, Graham RM. Selenium Status is Associated with insulin resistance markers in adults: findings from the 2013 to 2018 National Health and Nutrition Examination Survey (NHANES). Front Nutr. 2021. https://doi.org/10.3389/fnut.2021.696024.

17.

Stranges S, Laclaustra M, Ji C, Cappuccio FP, Navas-Acien A, Ordovas JM, et al. Higher selenium status is associated with adverse blood lipid profile in british adults. J Nutr. 2010. https://doi.org/10.3945/jn.109.111252.

18.

Laclaustra M, Stranges S, Navas-Acien A, Ordovas JM, Guallar E. Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003–2004. Atherosclerosis. 2010. https://doi.org/10.1016/j.atherosclerosis.2010.01.005.

19.

Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and hypertension in the US Population. Circ Cardiovasc qual outcomes. Circ Cardiovasc Qual Outcomes. 2009. https://doi.org/10.1161/CIRCOUTCOMES.108.831552.

20.

Yang Z, Yan C, Liu G, Niu Y, Zhang W, Lu S, et al. Plasma selenium levels and nonalcoholic fatty liver disease in chinese adults: a cross-sectional analysis. Sci Rep. 2016. https://doi.org/10.1038/srep37288.

21.

Wu J, Zeng C, Yang Z, Li X, Lei G, Xie D, et al. Association between dietary selenium intake and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study. J Am Coll Nutr. 2020. https://doi.org/10.1080/07315724.2019.1613271.

22.

Dias JPV, Costa Sobrinho PS, Pimenta AM, Hermsdorff HHM, Bressan J, Nobre LN. Dietary selenium intake and Type-2 diabetes: a cross-sectional Population-Based study on CUME Project. Front Nutr. 2021. https://doi.org/10.3389/fnut.2021.678648.

23.

Aktary ML, Eller LK, Nicolucci AC, Reimer RA. Cross-sectional analysis of the health profile and dietary intake of a sample of canadian adults diagnosed with non-alcoholic fatty liver disease. Food Nutr Res. 2020. https://doi.org/10.29219/fnr.v64.4548.

24.

Vinceti M, Grioni S, Alber D, Consonni D, Malagoli C, Agnoli C, et al. Toenail selenium and risk of type 2 diabetes: the ORDET cohort study. J Trace Elem Med Biol. 2015. https://doi.org/10.1016/j.jtemb.2014.07.017.

25.

Safarpour AR, Fattahi MR, Niknam R, Tarkesh F, Mohammadkarimi V, Boogar SS, et al. Alarm of non-communicable disease in Iran: Kavar cohort profile, baseline and 18-month follow up results from a prospective population-based study in urban area. PLoS ONE. 2022. https://doi.org/10.1371/journal.pone.0260227.

26.

Xun P, Hou N, Daviglus M, Liu K, Morris JS, Shikany JM, et al. Fish oil, selenium and mercury in relation to incidence of hypertension: a 20-year follow-up study. J Intern Med. 2011. https://doi.org/10.1111/j.1365-2796.2010.02338.x.

27.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american Gastroenterological Association, American Association for the study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012. https://doi.org/10.1053/j.gastro.2012.04.001.

28.

Ariya M, Shahraki HR, Farjam M, Ehrampoush E, Bahramali E, Homayounfar R, et al. Dietary inflammatory index and metabolic syndrome in iranian population (Fasa Persian Cohort Study). Sci Rep. 2020. https://doi.org/10.1038/s41598-020-73844-0.

29.

Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr. 1997. https://doi.org/10.1093/ajcn/65.4.1220S.

30.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006. https://doi.org/10.1186/1471-230X-6-33.

31.

Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010. https://doi.org/10.1016/j.dld.2009.08.002.

32.

Moradinazar M, Najafi F, Jalilian F, Pasdar Y, Hamzeh B, Shakiba E, et al. Prevalence of drug use, alcohol consumption, cigarette smoking and measure of socioeconomic-related inequalities of drug use among iranian people: findings from a national survey. Subst Abuse Treat Prev Policy. 2020. https://doi.org/10.1186/s13011-020-00279-1.

33.

Stoffaneller R, Morse NL. A review of dietary selenium intake and selenium status in Europe and the Middle East. Nutrients. 2015; doi: https://doi.org/10.3390/nu7031494.

34.

Liu X, Shen H, Chen M, Shao J. Clinical relevance of selenium with liver stiffness and steatosis detected by transient elastography in adults. Biol Trace Elem Res. 2022. https://doi.org/10.1007/s12011-021-02912-x.

35.

Su L, Gao S, Unverzagt FW, Cheng Y, Hake AM, Xin P, et al. Selenium level and dyslipidemia in rural elderly chinese. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0136706.

36.

Christensen K, Werner M, Malecki K. Serum selenium and lipid levels: Associations observed in the National Health and Nutrition Examination Survey (NHANES) 2011–2012. Environ Res. 2015. https://doi.org/10.1016/j.envres.2015.03.020.

37.

Zhang Q-Q, Lu L-G. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015. https://doi.org/10.14218/JCTH.2014.00037.

38.

Steinbrenner H, Speckmann B, Pinto A. Sies HJJocb, nutrition. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr. 2010. https://doi.org/10.3164/jcbn.11-002FR.

39.

Mueller AS, Klomann SD, Wolf NM, Schneider S, Schmidt R, Spielmann J, et al. Redox regulation of protein tyrosine phosphatase 1B by manipulation of dietary selenium affects the triglyceride concentration in rat liver. J Nutr. 2008. https://doi.org/10.3945/jn.108.089482.

40.

Zhao Z, Barcus M, Kim J, Lum KL, Mills C, Lei XG. High dietary selenium intake alters lipid metabolism and protein synthesis in liver and muscle of pigs. J Nutr. 2016. https://doi.org/10.3945/jn.116.229955.

41.

Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014. https://doi.org/10.3748/wjg.v20.i2.475.

42.

Hsu C-L, Wu F-Z, Lin K-H, Chen Y-H, Wu P-C, Chen Y-H, et al. Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin Transl Gastroenterol. 2019. https://doi.org/10.14309/ctg.0000000000000042.

43.

Jones GS, Alvarez CS, Graubard BI, McGlynn KAJCG. Hepatology. Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient elastography and fatty liver indices. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2020.11.028.

44.

Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, et al. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol. 2021. https://doi.org/10.20524/aog.2021.0604.

45.

Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of non-alcoholic fatty liver Disease and its related factors in Iran. Int J Organ Transplant Med. 2016;7(3):149–60.

Title: Dietary selenium intake in relation to non-alcoholic fatty liver disease assessed by fatty liver index and hepatic steatosis index; a cross-sectional study on the baseline data of prospective PERSIAN Kavar cohort study.
Authors: Sara Shojaei Zarghani
Nima Rahimi Kashkooli
Zahra Bagheri
Mahdy Tabatabaei
Mohammad Reza Fattahi
Ali Reza Safarpour
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Fatty Liver
Published in: BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-023-01307-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Treatment of septic shock in two pediatric patients with severe diabetic ketoacidosis using invasive hemodynamic monitoring: a case report

Association of systemic immune-inflammation index (SII) and aggregate index of systemic inflammation (AISI) with thyroid nodules in patients with type 2 diabetes mellitus: a retrospective study

Dietary polyphenol intake, body composition and components of metabolic syndrome in a sample overweight and obese adults: a cross-sectional study

Prevalence and associated factors of foot deformity among adult diabetic patients on follow-up at Debre Markos comprehensive specialized hospital, Northwest Ethiopia, 2022, cross-sectional study

Bilateral co-secretory lesions, coexisting Cushing syndrome and primary aldosteronism

Prevalence of hyperuricemia among type 2 diabetes mellitus patients in Africa: a systematic review and meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials